Efficaty and safety of corneal collagen cross-linking for keratoconus, keratectasia and infectious keratitis

Efficaty and safety of corneal collagen cross-linking for keratoconus, keratectasia and infectious keratitis - Efficacy and safety of CXL for keratoconus and other diseases.

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000011350

Enrollment

Registered

2013-08-02

Start date

2010-04-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

keratoconus keratectasia infectious keratitis

Interventions

Observation period 1-2 years Exposure of UVA 3mW/cm2 for 30 minutes Adminisration of 0.1% ribofravin solution for 30 minutes before UVA exposure and 30 minutes during UVA exposure.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Progressive keratoconus or keratectasia Minimum corneal thickness 400 micrometers and more. Infectious keratitis sized less than 5mm

Exclusion criteria

Exclusion criteria: Corneal thickness less than 400 micrometers Unknown infectious keratitis Other ocular diseases

Design outcomes

Primary

Measure	Time frame
visual acuity refraction spherical equivalent endothelial cell density complication	—

Countries

Japan

Contacts

Public ContactKenji Konomi

Tokyo Dental College Ichikawa General Hospital Ophthalmology

jzt02060@nifty.ne.jp047-322-0151

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026